The purpose of this study is to determine the recommended Phase 2 dose (RP2D) candidate(s) of JNJ-75276617 in combination with AML directed therapies (dose selection) and further to evaluate safety and tolerability of JNJ-75276617 in combination with AML directed therapies at the RP2D(s) (dose expansion).
The purpose of this study is to determine the recommended Phase 2 dose(s) of JNJ-75276617 in combination with AML-targeted therapies (dose selection) and also to evaluate the safety and tolerability of JNJ-75276617 in combination with AML-targeted therapies in RP2D(s) (dose expansion).
